bluuebunny/crossref_metadata_2025 huggingface dataset:
Table S1 from Genetic Risk of Second Malignant Neoplasm after Childhood Cancer Treatment: A Systematic Review
Authors: Ducos Claire , Aba Naïla , Rosselli Filippo , Fresneau Brice , Al Ahmad Nachar Baraah , Zidane Monia , de Vathaire Florent , Benhamou Simone , Haddy Nadia
Published: August 2024

Table S1 displays all the keywords used to search articles in the Pubmed database.
Supplementary Figure 7 from Assessing the Relationship between Biomarkers of Exposure and Biomarkers of Potential Harm: PATH Study Wave 1 (2013 to 2014)
Authors: Chang Cindy M. , Thakur Sapna , Montes de Oca Ruben , Rostron Brian L. , Cheng Yu-Ching , Wright M. Jerry , van Bemmel Dana M. , Wang Lanqing , Hatsukami Dorothy K.
Published: August 2024

Supplementary Figure 7. Scatter plots of log-transformed BOPH ((A) sICAM (B) hs-CRP (C) IL-6 (D) Fibro (E) 8-Isoprostane) and log-transformed SCOT by Tobacco Use
Supplementary Figure 6 from Assessing the Relationship between Biomarkers of Exposure and Biomarkers of Potential Harm: PATH Study Wave 1 (2013 to 2014)
Authors: Chang Cindy M. , Thakur Sapna , Montes de Oca Ruben , Rostron Brian L. , Cheng Yu-Ching , Wright M. Jerry , van Bemmel Dana M. , Wang Lanqing , Hatsukami Dorothy K.
Published: August 2024

Supplementary Figure 6. Scatter plots of log-transformed BOPH ((A) sICAM (B) hs-CRP (C) IL-6 (D) Fibro (E) 8-Isoprostane) and log-transformed cadmium by Tobacco Use
Supplementary Figure 5 from Assessing the Relationship between Biomarkers of Exposure and Biomarkers of Potential Harm: PATH Study Wave 1 (2013 to 2014)
Authors: Chang Cindy M. , Thakur Sapna , Montes de Oca Ruben , Rostron Brian L. , Cheng Yu-Ching , Wright M. Jerry , van Bemmel Dana M. , Wang Lanqing , Hatsukami Dorothy K.
Published: August 2024

Supplementary Figure 5. Scatter plots of log-transformed BOPH ((A) sICAM (B) hs-CRP (C) IL-6 (D) Fibro (E) 8-Isoprostane) and log-transformed 1-OHP by Tobacco Use
Supplementary Figure 4 from Assessing the Relationship between Biomarkers of Exposure and Biomarkers of Potential Harm: PATH Study Wave 1 (2013 to 2014)
Authors: Chang Cindy M. , Thakur Sapna , Montes de Oca Ruben , Rostron Brian L. , Cheng Yu-Ching , Wright M. Jerry , van Bemmel Dana M. , Wang Lanqing , Hatsukami Dorothy K.
Published: August 2024

Supplementary Figure 4. Scatter plots of log-transformed BOPH ((A) sICAM (B) hs-CRP (C) IL-6 (D) Fibro (E) 8-Isoprostane) and log-transformed CYMA by Tobacco Use
Supplementary Figure 1 from Assessing the Relationship between Biomarkers of Exposure and Biomarkers of Potential Harm: PATH Study Wave 1 (2013 to 2014)
Authors: Chang Cindy M. , Thakur Sapna , Montes de Oca Ruben , Rostron Brian L. , Cheng Yu-Ching , Wright M. Jerry , van Bemmel Dana M. , Wang Lanqing , Hatsukami Dorothy K.
Published: August 2024

Supplementary Figure 1. Plots of geometric mean ratios (and 95% confidence intervals) comparing pairs of tobacco use groups
Table S1 from Racialized Economic Segregation and Treatment and Outcomes of Small Cell Lung Cancer
Authors: Bekele Bayu B. , Lian Min , Shrestha Pratibha , Nabi Oumarou , Kozower Benjamin , Baggstrom Maria Q. , Liu Ying
Published: August 2024

The overall and race-specific associations between racialized economic segregation and all-cause mortality in non-Hispanic White and non-Hispanic Black patients with small cell lung cancer
Supplementary Table S4 from Disparities and Determinants of Testing for Early Detection of Cervical Cancer among Nepalese Women: Evidence from a Population-Based Survey
Authors: Rahman Md. Shafiur , Rahman Md. Mahfuzur , Acharya Kiran , Haruyama Rei , Shah Richa , Matsuda Tomohiro , Inoue Manami , Abe Sarah K.
Published: August 2024

Supplementary Table S4 shows the values of slope index of inequality (with 95% CI) for the cervical cancer test uptake among Nepalese women.
Supplementary Table S3 from Disparities and Determinants of Testing for Early Detection of Cervical Cancer among Nepalese Women: Evidence from a Population-Based Survey
Authors: Rahman Md. Shafiur , Rahman Md. Mahfuzur , Acharya Kiran , Haruyama Rei , Shah Richa , Matsuda Tomohiro , Inoue Manami , Abe Sarah K.
Published: August 2024

Supplementary Table S3 shows the reasons for the uptake of cervical cancer test among Nepalese women by age groups.
Supplementary Figure S1 from Disparities and Determinants of Testing for Early Detection of Cervical Cancer among Nepalese Women: Evidence from a Population-Based Survey
Authors: Rahman Md. Shafiur , Rahman Md. Mahfuzur , Acharya Kiran , Haruyama Rei , Shah Richa , Matsuda Tomohiro , Inoue Manami , Abe Sarah K.
Published: August 2024

whom information on cervical cancer testing and other covariates available.
Supplemental Table 7 from Association of Urinary Biomarkers of Tobacco Exposure with Lung Cancer Risk in African American and White Cigarette Smokers in the Southern Community Cohort Study
Authors: Murphy Sharon E. , Guillermo Cherie , Thomson Nicole M. , Carmella Steven G. , Wittmann Milo , Aldrich Melinda C. , Cai Qiuyin , Sullivan Shannon M. , Stram Daniel O. , Le Marchand Loïc , Hecht Stephen S. , Blot William J. , Park S. Lani
Published: August 2024

Supplemental Table 7. Association of urinary biomarkers and lung cancer risk in Southern Community Cohort participants stratified by histologic cell-type
Table S7 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study
Authors: Ruffieux Yann , Fernández Villalobos Nathalie V. , Didden Christiane , Haas Andreas D. , Chinogurei Chido , Cornell Morna , Egger Matthias , Maartens Gary , Folb Naomi , Rohner Eliane
Published: August 2024

Table S7 shows rate ratios for prostate specific antigen testing (PSA) and prostate biopsies, with no left-truncation at first HIV positive marker.
Supplemental Table 1 from Association of Urinary Biomarkers of Tobacco Exposure with Lung Cancer Risk in African American and White Cigarette Smokers in the Southern Community Cohort Study
Authors: Murphy Sharon E. , Guillermo Cherie , Thomson Nicole M. , Carmella Steven G. , Wittmann Milo , Aldrich Melinda C. , Cai Qiuyin , Sullivan Shannon M. , Stram Daniel O. , Le Marchand Loïc , Hecht Stephen S. , Blot William J. , Park S. Lani
Published: August 2024

Supplemental Table 1. Coefficients of Variation for Biomarker analysis
Figure 2 from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study
Authors: Ruffieux Yann , Fernández Villalobos Nathalie V. , Didden Christiane , Haas Andreas D. , Chinogurei Chido , Cornell Morna , Egger Matthias , Maartens Gary , Folb Naomi , Rohner Eliane
Published: August 2024

Graph illustrating structural assumptions regarding factors potentially confounding (red nodes) or mediating (blue nodes) the effect of HIV on incident prostate cancer diagnosis. Age, population group, STIs, and other unmeasured factors are assumed to be related with both HIV status and prostate cancer diagnosis and may, therefore, confound the effect of HIV on the risk of incident prostate cancer diagnosis. PSA testing, prostate biopsies, and prostatitis are assumed to be related with HIV status and to affect prostate cancer diagnosis rates and may, thus, serve as mediators. The dashed (yellow) lines indicate influences where the direction is unknown. The (orange) arrow represents the effect of HIV on incident prostate cancer diagnosis, taking into account confounders and mediators. This effect is interpreted as the possible biological effect of HIV on the risk of a prostate cancer diagnosis.
Supplementary Table 2. from Joint Associations of Diet and Device-Measured Physical Activity with Mortality and Incident CVD and Cancer: A Prospective Analysis of the UK Biobank Study
Authors: Inan-Eroglu Elif , Ahmadi Matthew , Biswas Raaj Kishore , Ding Ding , Rezende Leandro F.M. , Lee I-Min , Giovannucci Edward L. , Stamatakis Emmanuel
Published: August 2024

Supplementary Table 2 presents the baseline characteristics of the study sample, which includes 79,988 individuals, categorized by the joint groups of moderate to vigorous physical activity and diet quality score.
Supplemental Table S3 from Rural–Urban Cancer Incidence and Trends in the United States, 2000 to 2019
Authors: Semprini Jason , Gadag Khyathi , Williams Gawain , Muldrow Aniyah , Zahnd Whitney E.
Published: August 2024

Supplemental Table S3: Rate Ratios for Age-adjusted cancer incidence rates by rural-urban status and sex, 2015 to 2019
Supplementary Figure 6 from Joint Associations of Diet and Device-Measured Physical Activity with Mortality and Incident CVD and Cancer: A Prospective Analysis of the UK Biobank Study
Authors: Inan-Eroglu Elif , Ahmadi Matthew , Biswas Raaj Kishore , Ding Ding , Rezende Leandro F.M. , Lee I-Min , Giovannucci Edward L. , Stamatakis Emmanuel
Published: August 2024

Joint association between physical activity and diet quality index with all-cause mortality and cardiovascular disease, total cancer and physical activity, diet and adiposity related cancer incidence.Supplementary Figure 6(A-D) shows the joint association between physical activity and diet quality index with all-cause mortality, cardiovascular disease, total cancer, and physical activity, diet, and adiposity-related cancer incidence (n = 79,988).
Data from Adverse Childhood Experiences, Resilience, and Cardiovascular Disease in Adult Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study
Authors: Schwartz Lindsay F. , Stratton Kayla L. , Leisenring Wendy M. , Rodriguez Stefania M. , Alston Shani , McDonald Aaron , Vukadinovich Chris , Rinehardt Dayton , Oeffinger Kevin C. , Chow Eric J. , Krull Kevin R. , Brinkman Tara M. , Nathan Paul C. , Tan Marcia M. , McCrae Julie S. , Burkhardt Tiffany , Ness Kirsten K. , Armstrong Gregory T. , Henderson Tara O.
Published: August 2024

AbstractBackground:
The impact of adverse childhood experiences (ACE, e.g., abuse, neglect, and/or household dysfunction experienced before the age of 18) and resilience on risk for cardiovascular disease (CVD) has not previously been investigated in adult survivors of childhood cancer.
Methods:
We conducted a nested case–control study among long-term, adult-aged survivors of childhood cancer from the Childhood Cancer Survivor Study. Self-report questionnaires ascertained ACEs and resilience, and scores were compared between cases with serious/life-threatening CVD and controls without CVD matched on demographic and cardiotoxic treatment factors.
Results:
Among 95 cases and 261 controls, the mean ACE score was 1.4 for both groups; 53.4% of survivors endorsed ≥1 ACE. No association was observed between ACEs or resilience and CVD in adjusted models.
Conclusions:
ACEs and resilience do not appear to contribute to CVD risk for adult survivors of childhood cancer with cardiotoxic treatment exposures.
Impact:
Although not associated with CVD in this population, ACEs are associated with serious health issues in other populations. Therefore, future studies could investigate the effects of ACEs on other health outcomes affecting childhood cancer survivors.
Data from Prostate Cancer Diagnosis Rates among Insured Men with and without HIV in South Africa: A Cohort Study
Authors: Ruffieux Yann , Fernández Villalobos Nathalie V. , Didden Christiane , Haas Andreas D. , Chinogurei Chido , Cornell Morna , Egger Matthias , Maartens Gary , Folb Naomi , Rohner Eliane
Published: August 2024

AbstractBackground:
Several studies have found lower prostate cancer diagnosis rates among men with human immunodeficiency virus (HIV; MWH) than men without HIV but reasons for this finding remain unclear.
Methods:
We used claims data from a South African private medical insurance scheme (July 2017– July 2020) to assess prostate cancer diagnosis rates among men aged ≥ 18 years with and without HIV. Using flexible parametric survival models, we estimated hazard ratios (HR) for the association between HIV and incident prostate cancer diagnoses. We accounted for potential confounding by age, population group, and sexually transmitted infections (confounder-adjusted model) and additionally for potential mediation by prostatitis diagnoses, prostate-specific antigen testing, and prostate biopsies (fully adjusted model).
Results:
We included 288,194 men, of whom 20,074 (7%) were living with HIV. Prostate cancer was diagnosed in 1,614 men without HIV (median age at diagnosis: 67 years) and in 82 MWH (median age at diagnosis: 60 years). In the unadjusted analysis, prostate cancer diagnosis rates were 35% lower among MWH than men without HIV [HR, 0.65; 95% confidence interval (CI), 0.52–0.82]. However, this association was no longer evident in the confounder-adjusted model (HR, 1.03; 95% CI, 0.82–1.30) or in the fully adjusted model (HR, 1.14; 95% CI, 0.91–1.44).
Conclusions:
When accounting for potential confounders and mediators, our analysis found no evidence of lower prostate cancer diagnosis rates among MWH than men without HIV in South Africa.
Impact:
Our results do not support the hypothesis that HIV decreases the risk of prostate cancer.
Supplementary Table S2 from A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated Melanoma
Authors: Embaby Alaa , Huijberts Sanne C.F.A. , Wang Liqin , Leite de Oliveira Rodrigo , Rosing Hilde , Nuijen Bastiaan , Sanders Joyce , Hofland Ingrid , van Steenis Charlaine , Kluin Roelof J.C. , Lieftink Cor , Smith Christopher G. , Blank Christian U. , van Thienen Johannes V. , Haanen John B.A.G. , Steeghs Neeltje , Opdam Frans L. , Beijnen Jos H. , Huitema Alwin D.R. , Bernards Rene , Schellens Jan H.M. , Wilgenhof Sofie
Published: August 2024

Supplementary Table S2. Tissue and ctDNA results.
Supplementary Table S8 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Authors: Tran Duc , Beeler J. Scott , Liu Jie , Wiley Brian , Chan Irenaeus C.C. , Xin Zilan , Kramer Michael H. , Batchi-Bouyou Armel L. , Zong Xiaoyu , Walter Matthew J. , Petrone Giulia E.M. , Chlamydas Sarantis , Ferraro Francesca , Oh Stephen T. , Link Daniel C. , Busby Ben , Cao Yin , Bolton Kelly L.
Published: August 2024

Association between plasma protein levels and biologically informed categories of clonal hematopoiesis (CH) genes.
Supplementary Figure S9 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Authors: Tran Duc , Beeler J. Scott , Liu Jie , Wiley Brian , Chan Irenaeus C.C. , Xin Zilan , Kramer Michael H. , Batchi-Bouyou Armel L. , Zong Xiaoyu , Walter Matthew J. , Petrone Giulia E.M. , Chlamydas Sarantis , Ferraro Francesca , Oh Stephen T. , Link Daniel C. , Busby Ben , Cao Yin , Bolton Kelly L.
Published: August 2024

Discrimination of MN risk integrating Clonal Hematopoiesis Risk Score (CHRS) and proteomics.
Supplementary Figure S8 from Plasma Proteomic Signature Predicts Myeloid Neoplasm Risk
Authors: Tran Duc , Beeler J. Scott , Liu Jie , Wiley Brian , Chan Irenaeus C.C. , Xin Zilan , Kramer Michael H. , Batchi-Bouyou Armel L. , Zong Xiaoyu , Walter Matthew J. , Petrone Giulia E.M. , Chlamydas Sarantis , Ferraro Francesca , Oh Stephen T. , Link Daniel C. , Busby Ben , Cao Yin , Bolton Kelly L.
Published: August 2024

Discrimination of MN risk using reduced set of proteomics features.
Supplemental Table 2 from Anastrozole Dose Escalation for Optimal Estrogen Suppression in Postmenopausal Early-Stage Breast Cancer: A Prospective Trial
Authors: Haddad Tufia C. , Suman Vera J. , Giridhar Karthik V. , Sideras Kostandinos , Northfelt Donald W. , Ernst Brenda J. , O’Sullivan Ciara C. , Singh Ravinder J. , Desta Zeruesenay , Peethambaram Prema P. , Hobday Timothy J. , Chumsri Saranya , Leon-Ferre Roberto A. , Ruddy Kathryn J. , Yadav Siddhartha , Taraba Jodi L. , Goodnature Barbara , Goetz Matthew P. , Wang Liewei , Ingle James N.
Published: August 2024

Supplemental Table 2: All adverse events among those patients who discontinued ANA1 early or did not continue onto ANA10 after IES finding due to toxicity.
Supplementary Table S5 from Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models
Authors: Jain Sonia , Griffith Jessica I. , Porath Kendra A. , Rathi Sneha , Le Jiayan , Pasa Tugce I. , Decker Paul A. , Gupta Shiv K. , Hu Zeng , Carlson Brett L. , Bakken Katrina , Burgenske Danielle M. , Feldsien Thomas M. , Lefebvre Didier R. , Vaubel Rachael A. , Eckel-Passow Jeanette E. , Reilly Edward B. , Elmquist William F. , Sarkaria Jann N.
Published: August 2024

Pharmacokinetics parameters
Supplementary Table S3 from Bystander Effects, Pharmacokinetics, and Linker-Payload Stability of EGFR-Targeting Antibody-Drug Conjugates Losatuxizumab Vedotin and Depatux-M in Glioblastoma Models
Authors: Jain Sonia , Griffith Jessica I. , Porath Kendra A. , Rathi Sneha , Le Jiayan , Pasa Tugce I. , Decker Paul A. , Gupta Shiv K. , Hu Zeng , Carlson Brett L. , Bakken Katrina , Burgenske Danielle M. , Feldsien Thomas M. , Lefebvre Didier R. , Vaubel Rachael A. , Eckel-Passow Jeanette E. , Reilly Edward B. , Elmquist William F. , Sarkaria Jann N.
Published: August 2024

In vitro EC50 values
Supplementary Table S5 from A 5-Hydroxymethylcytosine-Based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: The METHOD-2 Study
Authors: Chang Wenju , Zhang Zhou , Jia Baoqing , Ding Kefeng , Pan Zhizhong , Su Guoqiang , Zhang Wei , Liu Tianyu , Zhong Yunshi , He Guodong , Ren Li , Wei Ye , Li Dongdong , Cui Xiaolong , Yang Jun , Shi Yixiang , Bissonnette Marc , He Chuan , Zhang Wei , Fan Jia , Xu Jianmin
Published: August 2024

Enriched KEGG pathways
Supplementary Table S2 from A 5-Hydroxymethylcytosine-Based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: The METHOD-2 Study
Authors: Chang Wenju , Zhang Zhou , Jia Baoqing , Ding Kefeng , Pan Zhizhong , Su Guoqiang , Zhang Wei , Liu Tianyu , Zhong Yunshi , He Guodong , Ren Li , Wei Ye , Li Dongdong , Cui Xiaolong , Yang Jun , Shi Yixiang , Bissonnette Marc , He Chuan , Zhang Wei , Fan Jia , Xu Jianmin
Published: August 2024

Participant demographics and baseline characteristics.
Supplementary Table S1 from A 5-Hydroxymethylcytosine-Based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: The METHOD-2 Study
Authors: Chang Wenju , Zhang Zhou , Jia Baoqing , Ding Kefeng , Pan Zhizhong , Su Guoqiang , Zhang Wei , Liu Tianyu , Zhong Yunshi , He Guodong , Ren Li , Wei Ye , Li Dongdong , Cui Xiaolong , Yang Jun , Shi Yixiang , Bissonnette Marc , He Chuan , Zhang Wei , Fan Jia , Xu Jianmin
Published: August 2024

Participant demographics in training, internval validation, and external validation sets.
Supplementary Figure S6 from A 5-Hydroxymethylcytosine-Based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: The METHOD-2 Study
Authors: Chang Wenju , Zhang Zhou , Jia Baoqing , Ding Kefeng , Pan Zhizhong , Su Guoqiang , Zhang Wei , Liu Tianyu , Zhong Yunshi , He Guodong , Ren Li , Wei Ye , Li Dongdong , Cui Xiaolong , Yang Jun , Shi Yixiang , Bissonnette Marc , He Chuan , Zhang Wei , Fan Jia , Xu Jianmin
Published: August 2024

Performance of the 5hmC diagnostic model for CRC/AA in distinguishing stage I-III CRC and AA.
Supplementary Figure S3 from A 5-Hydroxymethylcytosine-Based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: The METHOD-2 Study
Authors: Chang Wenju , Zhang Zhou , Jia Baoqing , Ding Kefeng , Pan Zhizhong , Su Guoqiang , Zhang Wei , Liu Tianyu , Zhong Yunshi , He Guodong , Ren Li , Wei Ye , Li Dongdong , Cui Xiaolong , Yang Jun , Shi Yixiang , Bissonnette Marc , He Chuan , Zhang Wei , Fan Jia , Xu Jianmin
Published: August 2024

Overview of the 5hmC-Seal profiles in cfDNA samples.
Supplementary Figure S2 from A 5-Hydroxymethylcytosine-Based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: The METHOD-2 Study
Authors: Chang Wenju , Zhang Zhou , Jia Baoqing , Ding Kefeng , Pan Zhizhong , Su Guoqiang , Zhang Wei , Liu Tianyu , Zhong Yunshi , He Guodong , Ren Li , Wei Ye , Li Dongdong , Cui Xiaolong , Yang Jun , Shi Yixiang , Bissonnette Marc , He Chuan , Zhang Wei , Fan Jia , Xu Jianmin
Published: August 2024

Differentially modified genes and tissue relevance.
Supplementary Table S1 from Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting
Authors: Ventin Marco , Cattaneo Giulia , Arya Shahrzad , Jia Jingyu , Gelmi Maria C. , Sun Yi , Maggs Luke , Ksander Bruce R. , Verdijk Robert M. , Boland Genevieve M. , Jenkins Russell W. , Haq Rizwan , Jager Martine J. , Wang Xinhui , Ryeom Sandra , Ferrone Cristina R.
Published: August 2024

Supplementary Table S1. Score of B7-H3 expression of treatment-naïve primary UM tumor samples.
Supplementary Figure S4 from Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting
Authors: Ventin Marco , Cattaneo Giulia , Arya Shahrzad , Jia Jingyu , Gelmi Maria C. , Sun Yi , Maggs Luke , Ksander Bruce R. , Verdijk Robert M. , Boland Genevieve M. , Jenkins Russell W. , Haq Rizwan , Jager Martine J. , Wang Xinhui , Ryeom Sandra , Ferrone Cristina R.
Published: August 2024

Supplementary Figure S4. Macroscopic and microscopic inspection of livers from low and high tumor burden mice treated with iCas9.B7-H3 CAR T cells.
Supplementary Figure S2 from Chimeric Antigen Receptor T Cell with an Inducible Caspase-9 Suicide Gene Eradicates Uveal Melanoma Liver Metastases via B7-H3 Targeting
Authors: Ventin Marco , Cattaneo Giulia , Arya Shahrzad , Jia Jingyu , Gelmi Maria C. , Sun Yi , Maggs Luke , Ksander Bruce R. , Verdijk Robert M. , Boland Genevieve M. , Jenkins Russell W. , Haq Rizwan , Jager Martine J. , Wang Xinhui , Ryeom Sandra , Ferrone Cristina R.
Published: August 2024

Supplementary Figure S2. In vitro assessment of B7-H3 CAR T cell antitumor activity.
Table S1 from Exposure–Response and Subgroup Analyses to Support Body Weight–Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin Lymphoma
Authors: Zhang Zufei , Zhang Daping , Guo Wenchuan , Fenton Keenan , Narayanan Sujata , Jain Shweta , Jiang Joy , Castellino Sharon M. , Kelly Kara M. , Cole Peter D. , Keller Frank G. , Garg Amit , Chia Yen Lin
Published: August 2024

Exposure metrics of ADC and MMAE following intravenous administration of brentuximab vedotin 1.8 mg/kg Q3W in the PK subpopulation.
Figure S4 from Exposure–Response and Subgroup Analyses to Support Body Weight–Based Dosing of Brentuximab Vedotin in Children and Young Adults with Newly Diagnosed High-risk Classical Hodgkin Lymphoma
Authors: Zhang Zufei , Zhang Daping , Guo Wenchuan , Fenton Keenan , Narayanan Sujata , Jain Shweta , Jiang Joy , Castellino Sharon M. , Kelly Kara M. , Cole Peter D. , Keller Frank G. , Garg Amit , Chia Yen Lin
Published: August 2024

Comparison of cycle 1 Cave for ADC and MMAE exposures in patients with grade ≥3 neutropenic AEs and patients without grade ≥3 neutropenic AEs in the PK subpopulation.
Supplementary Table S9 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Authors: Pankova Valeriya , Krasny Lukas , Kerrison William , Tam Yuen B. , Chadha Madhumeeta , Burns Jessica , Wilding Christopher P. , Chen Liang , Chowdhury Avirup , Perkins Emma , Lee Alexander T.J. , Howell Louise , Guljar Nafia , Sisley Karen , Fisher Cyril , Chudasama Priya , Thway Khin , Jones Robin L. , Huang Paul H.
Published: August 2024

Supplementary Table S9: Summary of multivariable (MVA) Cox regression analyses assessing the association of clinicopathological factors and dedifferentiated liposarcoma (DDLPS) subgroups with local recurrence-free survival (LRFS), overall survival (OS) and metastasis-free survival (MFS).
Supplementary Table S6 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Authors: Pankova Valeriya , Krasny Lukas , Kerrison William , Tam Yuen B. , Chadha Madhumeeta , Burns Jessica , Wilding Christopher P. , Chen Liang , Chowdhury Avirup , Perkins Emma , Lee Alexander T.J. , Howell Louise , Guljar Nafia , Sisley Karen , Fisher Cyril , Chudasama Priya , Thway Khin , Jones Robin L. , Huang Paul H.
Published: August 2024

Supplementary Table S6: Clinicopathological characteristics of n=39 dedifferentiated liposarcoma (DDLPS). Summary features of the cohort. For continuous variables, the median, minimum (min) and maximum (max) values are indicated. For categorical variables, count and percentage are shown.
Supplementary Figure S7 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Authors: Pankova Valeriya , Krasny Lukas , Kerrison William , Tam Yuen B. , Chadha Madhumeeta , Burns Jessica , Wilding Christopher P. , Chen Liang , Chowdhury Avirup , Perkins Emma , Lee Alexander T.J. , Howell Louise , Guljar Nafia , Sisley Karen , Fisher Cyril , Chudasama Priya , Thway Khin , Jones Robin L. , Huang Paul H.
Published: August 2024

Supplementary Figure S7. Clinical characterisation of DDLPS subgroups.
Supplementary Figure S2 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Authors: Pankova Valeriya , Krasny Lukas , Kerrison William , Tam Yuen B. , Chadha Madhumeeta , Burns Jessica , Wilding Christopher P. , Chen Liang , Chowdhury Avirup , Perkins Emma , Lee Alexander T.J. , Howell Louise , Guljar Nafia , Sisley Karen , Fisher Cyril , Chudasama Priya , Thway Khin , Jones Robin L. , Huang Paul H.
Published: August 2024

Supplementary Figure S2. Validation of MMP14 expression in undifferentiated pleomorphic sarcoma (UPS), dedifferentiated liposarcoma (DDLPS) and leiomyosarcoma (LMS) by immunohistochemistry (IHC).
Supplementary Figure S1 from Clinical Implications and Molecular Features of Extracellular Matrix Networks in Soft Tissue Sarcomas
Authors: Pankova Valeriya , Krasny Lukas , Kerrison William , Tam Yuen B. , Chadha Madhumeeta , Burns Jessica , Wilding Christopher P. , Chen Liang , Chowdhury Avirup , Perkins Emma , Lee Alexander T.J. , Howell Louise , Guljar Nafia , Sisley Karen , Fisher Cyril , Chudasama Priya , Thway Khin , Jones Robin L. , Huang Paul H.
Published: August 2024

Supplementary Figure S1. The matrisome and adhesome profiles in soft tissue sarcoma (STS).
Supplementary Table S4 from A Pooled Analysis of Treatment-Free Survival in Advanced Renal Cell Carcinoma
Authors: Chang Elaine , Zhou Jiaxi , Song Chi , Gittleman Haley , Fernandes Laura , Weinstock Chana , Atkins Michael B. , Agrawal Sundeep , Sridhara Rajeshwari , Gormley Nicole , Tang Shenghui , Suzman Daniel L. , Amiri-Kordestani Laleh , Kluetz Paul G. , Pazdur Richard , Rini Brian I. , McDermott David F. , Regan Meredith M.
Published: August 2024

Timing of Discontinuation of TKI Relative to IO Agent
Supplementary Table Legend 1 from Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy
Authors: Bobin Charles , Iddir Yasmine , Butterworth Charlotte , Masliah-Planchon Julien , Saint-Charles Alexandra , Bellini Angela , Bhalshankar Jaydutt , Pierron Gaelle , Combaret Valérie , Attignon Valéry , André Nicolas , Corradini Nadège , Dumont Benoit , Mansuy Ludovic , Khanfar Camille , Klein Sebastien , Briandet Claire , Plantaz Dominique , Millot Frederic , Thouvenin Sandrine , Aerts Isabelle , Ndounga-Diakou Lee Aymar , Laghouati Salim , Abbou Samuel , Jehanno Nina , Tissot Hubert , Renault Shufang , Baulande Sylvain , Raynal Virginie , Bozec Laurence , Bieche Ivan , Delattre Olivier , Berlanga Pablo , Schleiermacher Gudrun
Published: August 2024

Supplementary Table Legend
Supplementary Table 3 from Sequential Analysis of cfDNA Reveals Clonal Evolution in Patients with Neuroblastoma Receiving ALK-Targeted Therapy
Authors: Bobin Charles , Iddir Yasmine , Butterworth Charlotte , Masliah-Planchon Julien , Saint-Charles Alexandra , Bellini Angela , Bhalshankar Jaydutt , Pierron Gaelle , Combaret Valérie , Attignon Valéry , André Nicolas , Corradini Nadège , Dumont Benoit , Mansuy Ludovic , Khanfar Camille , Klein Sebastien , Briandet Claire , Plantaz Dominique , Millot Frederic , Thouvenin Sandrine , Aerts Isabelle , Ndounga-Diakou Lee Aymar , Laghouati Salim , Abbou Samuel , Jehanno Nina , Tissot Hubert , Renault Shufang , Baulande Sylvain , Raynal Virginie , Bozec Laurence , Bieche Ivan , Delattre Olivier , Berlanga Pablo , Schleiermacher Gudrun
Published: August 2024

Supplementary Table 3
Supplementary Table S2 from Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Authors: Nguyen Charles B. , Reimers Melissa A. , Perera Chamila , Abida Wassim , Chou Jonathan , Feng Felix Y. , Antonarakis Emmanuel S. , McKay Rana R. , Pachynski Russell K. , Zhang Jingsong , Reichert Zachery R. , Palmbos Phillip L. , Caram Megan E.V. , Vaishampayan Ulka N. , Heath Elisabeth I. , Hopkins Alexander C. , Cieslik Marcin P. , Wu Yi-Mi , Robinson Dan R. , Baladandayuthapani Veerabhadran , Chinnaiyan Arul M. , Alva Ajjai S.
Published: August 2024

Supplementary Table S2. Objective response rate (ORR) and radiographic progression-free survival (rPFS).
Supplementary Figure S4 from Evaluating Immune Checkpoint Blockade in Metastatic Castration-Resistant Prostate Cancers with Deleterious CDK12 Alterations in the Phase 2 IMPACT Trial
Authors: Nguyen Charles B. , Reimers Melissa A. , Perera Chamila , Abida Wassim , Chou Jonathan , Feng Felix Y. , Antonarakis Emmanuel S. , McKay Rana R. , Pachynski Russell K. , Zhang Jingsong , Reichert Zachery R. , Palmbos Phillip L. , Caram Megan E.V. , Vaishampayan Ulka N. , Heath Elisabeth I. , Hopkins Alexander C. , Cieslik Marcin P. , Wu Yi-Mi , Robinson Dan R. , Baladandayuthapani Veerabhadran , Chinnaiyan Arul M. , Alva Ajjai S.
Published: August 2024

Supplementary Figure S4. Time to PSA progression (TTP).
Supplementary Table S1 from Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial
Authors: Loree Jonathan M. , Titmuss Emma , Topham James T. , Kennecke Hagen F. , Feilotter Harriet , Virk Shakeel , Lee Young S. , Banks Kimberly , Quinn Katie , Karsan Aly , Renouf Daniel J. , Jonker Derek J. , Tu Dongsheng , O’Callaghan Chris J. , Chen Eric X.
Published: August 2024

Supplemental Table 1. Representativeness of Study Participants
Supplementary Figure S5 from Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial
Authors: Loree Jonathan M. , Titmuss Emma , Topham James T. , Kennecke Hagen F. , Feilotter Harriet , Virk Shakeel , Lee Young S. , Banks Kimberly , Quinn Katie , Karsan Aly , Renouf Daniel J. , Jonker Derek J. , Tu Dongsheng , O’Callaghan Chris J. , Chen Eric X.
Published: August 2024

CHIP variants in CO.26.
Supplementary Figure S3 from Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial
Authors: Loree Jonathan M. , Titmuss Emma , Topham James T. , Kennecke Hagen F. , Feilotter Harriet , Virk Shakeel , Lee Young S. , Banks Kimberly , Quinn Katie , Karsan Aly , Renouf Daniel J. , Jonker Derek J. , Tu Dongsheng , O’Callaghan Chris J. , Chen Eric X.
Published: August 2024

Clonal plasma TMB as a biomarker of response in CO.26.
Supplementary Figure S2 from Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial
Authors: Loree Jonathan M. , Titmuss Emma , Topham James T. , Kennecke Hagen F. , Feilotter Harriet , Virk Shakeel , Lee Young S. , Banks Kimberly , Quinn Katie , Karsan Aly , Renouf Daniel J. , Jonker Derek J. , Tu Dongsheng , O’Callaghan Chris J. , Chen Eric X.
Published: August 2024

Multivariable models of plasma and tissue TMB as biomarkers in CO.26, and optimal threshold for tissue TMB.
Supplementary Figure S1 from Plasma versus Tissue Tumor Mutational Burden as Biomarkers of Durvalumab plus Tremelimumab Response in Patients with Metastatic Colorectal Cancer in the CO.26 Trial
Authors: Loree Jonathan M. , Titmuss Emma , Topham James T. , Kennecke Hagen F. , Feilotter Harriet , Virk Shakeel , Lee Young S. , Banks Kimberly , Quinn Katie , Karsan Aly , Renouf Daniel J. , Jonker Derek J. , Tu Dongsheng , O’Callaghan Chris J. , Chen Eric X.
Published: August 2024

Consort diagram for the CO.26 trial.
Elacestrant in ER+, HER2− Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups
Authors: Bardia Aditya , Cortés Javier , Bidard François-Clément , Neven Patrick , Garcia-Sáenz José , Aftimos Phillipe , O’Shaughnessy Joyce , Lu Janice , Tonini Giulia , Scartoni Simona , Paoli Alessandro , Binaschi Monica , Wasserman Tomer , Kaklamani Virginia
Published: August 2024

Purpose:

Elacestrant significantly prolonged progression-free survival (PFS) with manageable safety versus standard-of-care (SOC) endocrine therapy (ET) in patients with estrogen receptor–positive (ER+), HER2− metastatic breast cancer and tumors harboring estrogen receptor 1 (ESR1) mutation following ET plus a cyclin-dependent kinase 4/6 inhibitor (ET+CDK4/6i). In patients with ESR1-mutated tumors, we evaluated the efficacy and safety of elacestrant versus SOC based on prior ET+CDK4/6i duration and in clinical subgroups with prior ET+CDK4/6i ≥12 months.

Patients and Methods:

EMERALD, an open-label phase III trial, randomly assigned patients with ER+, HER2− metastatic breast cancer who had received 1–2 prior lines of ET, mandatory CDK4/6i, and ≤1 chemotherapy to elacestrant (345 mg daily) or SOC (aromatase inhibitor or fulvestrant). PFS was assessed across subgroups in post hoc exploratory analyses without adjustment for multiple testing.

Results:

In patients with ESR1-mutated tumors and prior ET+CDK4/6i ≥12 months, the median PFS for elacestrant versus SOC was 8.6 versus 1.9 months (HR, 0.41; 95% confidence interval, 0.26–0.63). In this population, the median PFS (in months) for elacestrant versus SOC was 9.1 versus 1.9 (bone metastases), 7.3 versus 1.9 (liver and/or lung metastases), 9.0 versus 1.9 (<3 metastatic sites), 10.8 versus 1.8 (≥3 metastatic sites), 5.5 versus 1.9 (PIK3 catalytic subunit α mutation), 8.6 versus 1.9 (tumor protein p53 gene mutation), 9.0 versus 1.9 (HER2-low), 9.0 versus 1.9 (ESR1D538G-mutated tumors), and 9.0 versus 1.9 (ESR1Y537S/N-mutated tumors). Subgroup safety was consistent with the overall population.

Conclusions:

The duration of prior ET+CDK4/6i ≥12 months in metastatic breast cancer was associated with a clinically meaningful improvement in PFS for elacestrant compared with SOC and was consistent across all subgroups evaluated in patients with ER+, HER2−, ESR1-mutated tumors.
Supplementary Figure legend from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
Authors: Kong Ying , Zhao Xinyue , Wang Zhaofu , Yuan Siqi , Chen Sheng , Lou Shidi , Ma Shichao , Li Yunfeng , Wang Xinghao , Ge Yangfeng , Li Guobin , Yang Hongbing , Zhao Mengxi , Li Dandan , Zhang Hailong , Tan Wenfu , Wang Juan
Published: August 2024

Supplementary Figure legend
Figure S7 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
Authors: Kong Ying , Zhao Xinyue , Wang Zhaofu , Yuan Siqi , Chen Sheng , Lou Shidi , Ma Shichao , Li Yunfeng , Wang Xinghao , Ge Yangfeng , Li Guobin , Yang Hongbing , Zhao Mengxi , Li Dandan , Zhang Hailong , Tan Wenfu , Wang Juan
Published: August 2024

Body weight of mice over the time period of treatments.
Figure S6 from A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity
Authors: Kong Ying , Zhao Xinyue , Wang Zhaofu , Yuan Siqi , Chen Sheng , Lou Shidi , Ma Shichao , Li Yunfeng , Wang Xinghao , Ge Yangfeng , Li Guobin , Yang Hongbing , Zhao Mengxi , Li Dandan , Zhang Hailong , Tan Wenfu , Wang Juan
Published: August 2024

BR-cpd7 suppresses tumor cell proliferation. A, KATO III cells were treated with BR-cpd7 or BGJ398 for 5 days. Cell proliferation was assessed with CellTiter-Glo (n=3 replicates). B, Immunoblot analysis of FGFR2 and PARP in KATO III cells after 40 h of incubation with BGJ398, BR-cpd7 or BR-cpd7 NC at 10, 100 or 1000 nM (n=3 replicates).
Supplementary Figure S7 from INA03: A Potent Transferrin-Competitive Antibody–Drug Conjugate against CD71 for Safer Acute Leukemia Treatment
Authors: Bratti Manuela , Stubbs Elisa , Kolodych Sergii , Souchet Herve , Kelly Lois , Merlin Johanna , Marchal Michelle , Castellano Remy , Josselin Emmanuelle , Pasquer Hélène , Benajiba Lina , Puissant Alexandre , Koniev Oleksandr , Collette Yves , Belanger Coralie , Hermine Olivier , Monteiro Renato C. , Launay Pierre
Published: August 2024

Figure S7
Supplemental Figure S4 from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma
Authors: Collins Victor J. , Ludwig Katelyn R. , Nelson Ariana E. , Sundara Rajan Soumya , Yeung Choh , Vulikh Ksenia , Isanogle Kristine A. , Mendoza Arnulfo , Difilippantonio Simone , Karim Baktiar O. , Caplen Natasha J. , Heske Christine M.
Published: August 2024

The DNA-PKi enhancement of EWS cells sensitivity to etoposide DNA-PK inhibition is a class effect
Table S3 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
Authors: Rodriguez Bertha L. , Huang Jiawei , Gibson Laura , Fradette Jared J. , Chen Hung-I.H. , Koyano Kikuye , Cortez Czrina , Li Betty , Ho Carmence , Ashique Amir M. , Lin Vicky Y. , Crawley Suzanne , Roda Julie M. , Chen Peirong , Fan Bin , Kim Jeong , Sissons James , Sitrin Jonathan , Kaplan Daniel D. , Gibbons Don L. , Rivera Lee B.
Published: August 2024

Summary of patient samples used for evaluating LAIR1 expression on immune cells in blood and matched tumors.
Figure S1 from Antitumor Activity of a Novel LAIR1 Antagonist in Combination with Anti-PD1 to Treat Collagen-Rich Solid Tumors
Authors: Rodriguez Bertha L. , Huang Jiawei , Gibson Laura , Fradette Jared J. , Chen Hung-I.H. , Koyano Kikuye , Cortez Czrina , Li Betty , Ho Carmence , Ashique Amir M. , Lin Vicky Y. , Crawley Suzanne , Roda Julie M. , Chen Peirong , Fan Bin , Kim Jeong , Sissons James , Sitrin Jonathan , Kaplan Daniel D. , Gibbons Don L. , Rivera Lee B.
Published: August 2024

LAIR1 expression on circulating immune cells in normal healthy donors and patients diagnosed with solid cancers and undergoing checkpoint inhibition.
Supplemental Figure 8 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0
Authors: Markowitz Joseph , Shamblott Michael , Brohl Andrew S. , Sarnaik Amod A. , Eroglu Zeynep , Khushalani Nikhil I. , Dukes Christopher W. , Chamizo Alejandra , Bastawrous Marina , Garcia Edward T. , Dehlawi Ashraf , Chen Pei-Ling , De Aquino Deanryan B. , Sondak Vernon K. , Tarhini Ahmad A. , Kim Youngchul , Lawman Patricia , Pilon-Thomas Shari
Published: August 2024

Supplemental Figure 8: Nucleic Acid Sequence of pAc/emm55 Construct with Amino Acid Translation
Supplemental Figure 2 from First-in-Human Stage III/IV Melanoma Clinical Trial of Immune Priming Agent IFx-Hu2.0
Authors: Markowitz Joseph , Shamblott Michael , Brohl Andrew S. , Sarnaik Amod A. , Eroglu Zeynep , Khushalani Nikhil I. , Dukes Christopher W. , Chamizo Alejandra , Bastawrous Marina , Garcia Edward T. , Dehlawi Ashraf , Chen Pei-Ling , De Aquino Deanryan B. , Sondak Vernon K. , Tarhini Ahmad A. , Kim Youngchul , Lawman Patricia , Pilon-Thomas Shari
Published: August 2024

Supplemental Figure 2: Cytokine/chemokines increased or decreased after therapy in individual patients with the IO panel. The
Supplementary Table S2 from Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window
Authors: Satomaa Tero , Pynnönen Henna , Aitio Olli , Hiltunen Jukka O. , Pitkänen Virve , Lähteenmäki Tuula , Kotiranta Titta , Heiskanen Annamari , Hänninen Anna-Liisa , Niemelä Ritva , Helin Jari , Kuusanmäki Heikki , Vänttinen Ida , Rathod Ramji , Nieminen Anni I. , Yatkin Emrah , Heckman Caroline A. , Kontro Mika , Saarinen Juhani
Published: August 2024

Pharmacokinetic parameters of single i.v. dose mouse xenograft tumor models.
Supplementary Figure S5 from Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab–Auristatin Conjugate with a Wide Therapeutic Window
Authors: Satomaa Tero , Pynnönen Henna , Aitio Olli , Hiltunen Jukka O. , Pitkänen Virve , Lähteenmäki Tuula , Kotiranta Titta , Heiskanen Annamari , Hänninen Anna-Liisa , Niemelä Ritva , Helin Jari , Kuusanmäki Heikki , Vänttinen Ida , Rathod Ramji , Nieminen Anni I. , Yatkin Emrah , Heckman Caroline A. , Kontro Mika , Saarinen Juhani
Published: August 2024

Characterization of overconjugated GLK-33 batch in rat tolerability and toxicokinetic study.
Supplemental Figure 7 from Blockade of Discoidin Domain Receptor Signaling with Sitravatinib Reveals DDR2 as a Mediator of Neuroblastoma Pathogenesis and Metastasis
Authors: Rozen Esteban J. , Frantz William , Wigglesworth Kim , Vessella Theadora , Zhou Hong S. , Shohet Jason M.
Published: August 2024

Expression of DDR2 transcriptional targets PCOLCE and MAGED4B is highly enriched in Neuroblastoma cell lines.
Supplemental Figure 6 from Blockade of Discoidin Domain Receptor Signaling with Sitravatinib Reveals DDR2 as a Mediator of Neuroblastoma Pathogenesis and Metastasis
Authors: Rozen Esteban J. , Frantz William , Wigglesworth Kim , Vessella Theadora , Zhou Hong S. , Shohet Jason M.
Published: August 2024

Overexpression of DDR2 in 293 T cells renders these cells less sensitive to Sitravatinib inhibition of DDR2 signaling.
Supplemental Figure 5 from Blockade of Discoidin Domain Receptor Signaling with Sitravatinib Reveals DDR2 as a Mediator of Neuroblastoma Pathogenesis and Metastasis
Authors: Rozen Esteban J. , Frantz William , Wigglesworth Kim , Vessella Theadora , Zhou Hong S. , Shohet Jason M.
Published: August 2024

Relative weight (%) along time (age) of mice from Th-MYCN tumor model from Figure 3).
Supplemental Figure 3 from Blockade of Discoidin Domain Receptor Signaling with Sitravatinib Reveals DDR2 as a Mediator of Neuroblastoma Pathogenesis and Metastasis
Authors: Rozen Esteban J. , Frantz William , Wigglesworth Kim , Vessella Theadora , Zhou Hong S. , Shohet Jason M.
Published: August 2024

Sitravatinib inhibits proliferation of neuroblastoma cell lines.
Table S3 from TNIK Inhibition Sensitizes TNIK-Overexpressing Lung Squamous Cell Carcinoma to Radiotherapy
Authors: Nguyen Triet , Carrieri Francesca A. , Connis Nick , Lafargue Audrey , Chang Jinhee , Chan Aaron , Shetty Amol C. , Song Yang , Hoang Tung , Jagtap Shreya , Chowdhury Dipanwita D. , Khan Muhammad A. , Gabrielson Kathleen L. , Rezaee Mohammad , Torres-Ayuso Pedro , Brognard John , Hann Christine L. , Tran Phuoc T.
Published: August 2024

Primers used for RT-qPCR.
Figure S9 from TNIK Inhibition Sensitizes TNIK-Overexpressing Lung Squamous Cell Carcinoma to Radiotherapy
Authors: Nguyen Triet , Carrieri Francesca A. , Connis Nick , Lafargue Audrey , Chang Jinhee , Chan Aaron , Shetty Amol C. , Song Yang , Hoang Tung , Jagtap Shreya , Chowdhury Dipanwita D. , Khan Muhammad A. , Gabrielson Kathleen L. , Rezaee Mohammad , Torres-Ayuso Pedro , Brognard John , Hann Christine L. , Tran Phuoc T.
Published: August 2024

TNIK inhibition altered the cell cycle and promoted cell death post-IR.
Figure S8 from TNIK Inhibition Sensitizes TNIK-Overexpressing Lung Squamous Cell Carcinoma to Radiotherapy
Authors: Nguyen Triet , Carrieri Francesca A. , Connis Nick , Lafargue Audrey , Chang Jinhee , Chan Aaron , Shetty Amol C. , Song Yang , Hoang Tung , Jagtap Shreya , Chowdhury Dipanwita D. , Khan Muhammad A. , Gabrielson Kathleen L. , Rezaee Mohammad , Torres-Ayuso Pedro , Brognard John , Hann Christine L. , Tran Phuoc T.
Published: August 2024

DNA-PK inhibition enhanced TNIK inhibition-induced radiosensitization.
Figure S7 from TNIK Inhibition Sensitizes TNIK-Overexpressing Lung Squamous Cell Carcinoma to Radiotherapy
Authors: Nguyen Triet , Carrieri Francesca A. , Connis Nick , Lafargue Audrey , Chang Jinhee , Chan Aaron , Shetty Amol C. , Song Yang , Hoang Tung , Jagtap Shreya , Chowdhury Dipanwita D. , Khan Muhammad A. , Gabrielson Kathleen L. , Rezaee Mohammad , Torres-Ayuso Pedro , Brognard John , Hann Christine L. , Tran Phuoc T.
Published: August 2024

TNIK inhibition caused elevated DNA damage levels in TNIKhigh cells post-IR.
Figure S12 from TNIK Inhibition Sensitizes TNIK-Overexpressing Lung Squamous Cell Carcinoma to Radiotherapy
Authors: Nguyen Triet , Carrieri Francesca A. , Connis Nick , Lafargue Audrey , Chang Jinhee , Chan Aaron , Shetty Amol C. , Song Yang , Hoang Tung , Jagtap Shreya , Chowdhury Dipanwita D. , Khan Muhammad A. , Gabrielson Kathleen L. , Rezaee Mohammad , Torres-Ayuso Pedro , Brognard John , Hann Christine L. , Tran Phuoc T.
Published: August 2024

TNIK inhibition caused increased tumor necrosis when combined with radiotherapy in LK2 subcutaneous tumors.
Figure S11 from TNIK Inhibition Sensitizes TNIK-Overexpressing Lung Squamous Cell Carcinoma to Radiotherapy
Authors: Nguyen Triet , Carrieri Francesca A. , Connis Nick , Lafargue Audrey , Chang Jinhee , Chan Aaron , Shetty Amol C. , Song Yang , Hoang Tung , Jagtap Shreya , Chowdhury Dipanwita D. , Khan Muhammad A. , Gabrielson Kathleen L. , Rezaee Mohammad , Torres-Ayuso Pedro , Brognard John , Hann Christine L. , Tran Phuoc T.
Published: August 2024

TNIK inhibition promoted micronucleus formation in LSCC cells post-ionizing radiation.
Data from Enhancing Standard of Care Chemotherapy Efficacy Using DNA-Dependent Protein Kinase (DNA-PK) Inhibition in Preclinical Models of Ewing Sarcoma
Authors: Collins Victor J. , Ludwig Katelyn R. , Nelson Ariana E. , Sundara Rajan Soumya , Yeung Choh , Vulikh Ksenia , Isanogle Kristine A. , Mendoza Arnulfo , Difilippantonio Simone , Karim Baktiar O. , Caplen Natasha J. , Heske Christine M.
Published: August 2024

Abstract
Disruption of DNA damage repair via impaired homologous recombination is characteristic of Ewing sarcoma (EWS) cells. We hypothesize that this disruption results in increased reliance on nonhomologous end joining to repair DNA damage. In this study, we investigated if pharmacologic inhibition of the enzyme responsible for nonhomologous end joining, the DNA-PK holoenzyme, alters the response of EWS cells to genotoxic standard of care chemotherapy. We used analyses of cell viability and proliferation to investigate the effects of clinical DNA-PK inhibitors (DNA-PKi) in combination with six therapeutic or experimental agents for EWS. We performed calculations of synergy using the Loewe additivity model. Immunoblotting evaluated treatment effects on DNA-PK, DNA damage, and apoptosis. Flow cytometric analyses evaluated effects on cell cycle and fate. We used orthotopic xenograft models to interrogate tolerability, drug mechanism, and efficacy in vivo. DNA-PKi demonstrated on-target activity, reducing phosphorylated DNA-PK levels in EWS cells. DNA-PKi sensitized EWS cell lines to agents that function as topoisomerase 2 (TOP2) poisons and enhanced the DNA damage induced by TOP2 poisons. Nanomolar concentrations of single-agent TOP2 poisons induced G2M arrest and little apoptotic response while adding DNA-PKi-mediated apoptosis. In vivo, the combination of AZD7648 and etoposide had limited tolerability but resulted in enhanced DNA damage, apoptosis, and EWS tumor shrinkage. The combination of DNA-PKi with standard of care TOP2 poisons in EWS models is synergistic, enhances DNA damage and cell death, and may form the basis of a promising future therapeutic strategy for EWS.